{"id":5908,"date":"2024-08-08T11:00:00","date_gmt":"2024-08-08T05:30:00","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=5908"},"modified":"2025-05-28T12:13:33","modified_gmt":"2025-05-28T06:43:33","slug":"metastatic-her2-positive-breast-cancer","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/metastatic-her2-positive-breast-cancer","title":{"rendered":"Metastatic HER2-Positive Breast Cancer Landscape: What You Need to Know"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69d2ab8c900a9\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69d2ab8c900a9\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/metastatic-her2-positive-breast-cancer\/#Metastatic_HER2-Positive_Breast_Cancer\" >Metastatic HER2-Positive Breast Cancer<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/metastatic-her2-positive-breast-cancer\/#Metastatic_HER2-Positive_Breast_Cancer_Symptoms\" >Metastatic HER2-Positive Breast Cancer Symptoms<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/metastatic-her2-positive-breast-cancer\/#Diagnosis_of_Metastatic_HER2-Positive_Breast_Cancer\" >Diagnosis of Metastatic HER2-Positive Breast Cancer<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/metastatic-her2-positive-breast-cancer\/#What_is_the_Metastatic_HER2-Positive_Breast_Cancer_Prevalence\" >What is the Metastatic HER2-Positive Breast Cancer Prevalence?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/metastatic-her2-positive-breast-cancer\/#Metastatic_HER2-Positive_Breast_Cancer_Therapy_Landscape\" >Metastatic HER2-Positive Breast Cancer Therapy Landscape<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/www.delveinsight.com\/blog\/metastatic-her2-positive-breast-cancer\/#Metastatic_HER2-Positive_Breast_Cancer_Pipeline\" >Metastatic HER2-Positive Breast Cancer Pipeline<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/www.delveinsight.com\/blog\/metastatic-her2-positive-breast-cancer\/#Conclusion\" >Conclusion<\/a><\/li><\/ul><\/nav><\/div>\n\n<p>Breast cancer is not a single disease leading to abnormal cell division in breast tissues. Breast cancer is the most common form of cancer in women. Each year, it affects over 2 million women globally and is the most significant cause of death among women.&nbsp; According to DelveInsight\u2019s estimates, there were around 297K new cases of female breast cancer in the United States in 2023.<\/p>\n\n\n\n<p>Based on the menopausal status of women suffering from breast cancer, in the US, a higher number of cases were observed for the postmenopausal Breast cancer, accounting for 80\u201320% of the cases, while premenopausal women contributed a significantly lesser proportion of the patients.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-metastatic-her2-positive-breast-cancer\"><span class=\"ez-toc-section\" id=\"Metastatic_HER2-Positive_Breast_Cancer\"><\/span>Metastatic HER2-Positive Breast Cancer<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Metastatic HER2-Positive Breast Cancer is a type of breast cancer where biopsy tests of the cancerous cells show a positive status for a protein receptor called human epidermal growth factor receptor 2 (HER2). This receptor protein, when functioning normally, regulates the healthy division and growth of breast cells. In HER2-positive breast cancer, the cancer cells have an overexpression of the HER2 protein, leading to rapid and uncontrolled cell growth. This aggressive form of cancer often spreads to other parts of the body, making it more challenging to treat.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-metastatic-her2-positive-breast-cancer-symptoms\"><span class=\"ez-toc-section\" id=\"Metastatic_HER2-Positive_Breast_Cancer_Symptoms\"><\/span>Metastatic HER2-Positive Breast Cancer Symptoms<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Like many types of breast cancer, <strong>Metastatic HER2-Positive Breast Cancer symptoms <\/strong>may not be immediately obvious. When they do manifest, they can include changes in the size, shape, or contour of the breast; the presence of a mass or lump as small as a pea; a persistent lump or thickening in the breast or underarm area; alterations in the skin&#8217;s appearance on the breast or nipple, such as dimpling, puckering, scaling, inflammation, or discoloration; a marble-like hardened area under the skin; and discharge from the nipple that is either blood-stained or clear.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-diagnosis-of-metastatic-her2-positive-breast-cancer\"><span class=\"ez-toc-section\" id=\"Diagnosis_of_Metastatic_HER2-Positive_Breast_Cancer\"><\/span>Diagnosis of Metastatic HER2-Positive Breast Cancer<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Healthcare providers diagnose all breast cancers, including Metastatic HER2-Positive Breast Cancer, with breast biopsies. If these biopsies reveal cancer, a medical pathologist will examine the breast tissue cells for signs of HER2 proteins using laboratory tests, crucial for breast cancer diagnosis. The immunohistochemistry (IHC) test, which uses immunostaining to detect HER2 protein levels in cancerous cells, is a common method. To confirm IHC test results, pathologists may employ fluorescence in situ hybridization (FISH), a test that identifies extra copies of the HER2 gene. If lab tests indicate normal HER2 protein or gene levels, the breast cancer is classified as HER2-negative. Conversely, high levels of HER2 proteins or genes signify HER2-positive breast cancer.<\/p>\n\n\n\n<p>Pathologists further categorize this cancer subtype using a scoring system based on the HER2 protein levels in a breast tissue sample. For example, a score of 0 or 1+ indicates low levels of HER2 protein and a negative classification. A score of 2+ suggests moderate levels, prompting additional FISH testing to confirm results. A score of 3+ indicates many cancerous cells with high protein levels, classifying the sample as positive. This comprehensive approach ensures accurate breast cancer diagnosis and appropriate treatment planning for Metastatic HER2-Positive Breast Cancer.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-what-is-the-metastatic-her2-positive-breast-cancer-prevalence\"><span class=\"ez-toc-section\" id=\"What_is_the_Metastatic_HER2-Positive_Breast_Cancer_Prevalence\"><\/span>What is the Metastatic HER2-Positive Breast Cancer Prevalence?<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>According to the World Health Organization (WHO), breast cancer resulted in 670K deaths worldwide in 2022. According to DelveInsight\u2019s estimates, the total <a href=\"https:\/\/www.delveinsight.com\/report-store\/her2-positive-breast-cancer-epidemiology-forecast\"><strong>incident population of HER2-positive breast cancer<\/strong><\/a> in the seven major markets was nearly 102K cases in 2023. The cases in the 7MM are expected to increase during the forecast period, i.e., 2024\u20132034. The HR+\/HER2+ breast cases were highest in the United States, accounting for ~32K cases. According to the estimates, most cases of HER2-positive breast cancer occur in people between 40 and 60 in the United States, accounting for ~52% of total cases in 2023. Among EU4 and the UK, Germany had the maximum total incident cases of HER2-positive breast cancer, with ~11K cases in 2023, while Spain accounted for the least number of cases. In Japan, stage-specific cases of HER2-positive breast cancer were highest in Stage II, accounting for ~6K cases in 2023. The <a href=\"https:\/\/www.delveinsight.com\/report-store\/metastatic-her2-positive-breast-cancer-epidemiology-forecast\"><strong>Metastatic HER2-positive breast Cancer prevalence<\/strong><\/a> indicates a significant impact on healthcare systems across these regions.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-metastatic-her2-positive-breast-cancer-therapy-landscape\"><span class=\"ez-toc-section\" id=\"Metastatic_HER2-Positive_Breast_Cancer_Therapy_Landscape\"><\/span>Metastatic HER2-Positive Breast Cancer Therapy Landscape<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The <a href=\"https:\/\/www.delveinsight.com\/report-store\/metastatic-her2-positive-breast-cancer-market\">Metastatic HER-2 Positive Breast Cancer Market<\/a> comprises a variety of treatment options, which are mainly categorized into pharmacological and non-pharmacological therapies.<\/p>\n\n\n\n<p>Although the first-line treatment of metastatic breast cancer is mainly dependent on the receptor status, both estrogen and progesterone receptor status and HER2 receptor status should be tested.<\/p>\n\n\n\n<p>Numerous treatment options for HER2-positive breast cancer are available, spanning both pharmacological and nonpharmacological categories. Recent advancements in HER2 treatments have improved the management of HER2-positive breast cancer, yet relapse remains a significant challenge due to disease heterogeneity and drug resistance mechanisms.<\/p>\n\n\n\n<p>Traditionally, patients with metastatic HER2+ breast cancer were treated with conventional chemotherapy regimens until the advent of trastuzumab. In response to the rise of biosimilars, Roche introduced a subcutaneous (SC) formulation of <a href=\"https:\/\/www.delveinsight.com\/report-store\/tukysa-tucatinib-herceptin-trastuzumab-emerging-drug-insight-and-market-forecast\"><strong>HERCEPTIN<\/strong><\/a> in the EU in 2013 and the US in 2019, even with biosimilars available. Continuing to expand its HER2 franchise, Roche&#8217;s first ADC, KADCYLA, received FDA approval in 2013 for treating HER2-positive metastatic breast cancer following prior treatment with HERCEPTIN and chemotherapy. The second ADC to gain FDA and EMA approval is ENHERTU (trastuzumab deruxtecan), potentially revolutionizing the second-line treatment landscape and serving as a significant breakthrough for AstraZeneca and Daiichi.<\/p>\n\n\n\n<p>An emerging therapy, SYD985, is making strides in this competitive landscape, including filing a Biologics License Application (BLA) in the US and EU. Several companies, such as Pfizer, Roche, Spectrum Pharmaceuticals, Hoffmann-La Roche, Eli Lilly and Company, and Ambrx, are actively engaged in mid- and late-stage research and development for HER2-positive breast cancer.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-metastatic-her2-positive-breast-cancer-pipeline\"><span class=\"ez-toc-section\" id=\"Metastatic_HER2-Positive_Breast_Cancer_Pipeline\"><\/span>Metastatic HER2-Positive Breast Cancer Pipeline<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The <a href=\"https:\/\/www.delveinsight.com\/report-store\/metastatic-her2-positive-breast-cancer-pipeline-insight\"><strong>metastatic HER2-positive breast cancer pipeline<\/strong><\/a> is marked by a promising array of potential therapeutics despite its currently limited options. Companies like Byondis (SYD985), Roche (Giredestrant), Ambrx (ARX788), and Zymeworks\/Jazz Pharmaceuticals (Zanidatamab) are leading mid- and late-stage research efforts in this field. ARX788, an anti-HER2 antibody-drug conjugate (ADC) from Ambrx, is undergoing Phase II trials and has demonstrated a favorable safety profile and preliminary efficacy in heavily pre-treated <a href=\"https:\/\/www.delveinsight.com\/report-store\/her2-positive-breast-cancer-epidemiology-forecast\"><strong>HER2-positive breast cancer patients<\/strong><\/a>. Zanidatamab zovodotin, developed by Zymeworks\/Jazz Pharmaceuticals, combines a HER2-targeted bispecific ADC with a proprietary cytotoxic agent and is currently being evaluated in Phase II trials. Recent data from the Phase IIa trial presented at the San Antonio Breast Cancer Symposium (SABCS) 2023 highlights its manageable safety profile and effectiveness in HR+\/HER2+ metastatic breast cancer.<\/p>\n\n\n\n<p>Roche&#8217;s Giredestrant (RG6171, GDC-9545) represents a novel approach as a selective estrogen receptor degrader (SERD), which targets estrogen receptors to enhance degradation. This drug is in a Phase III trial, combined with PHESGO, for first-line maintenance in HR+\/HER2+ breast cancer. With expectations for future filing in 2026 and beyond, Giredestrant underscores the optimistic outlook for advancements in the metastatic HER2-positive breast cancer therapeutics market.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span>Conclusion<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The landscape of metastatic HER2-positive breast cancer treatment and research is rapidly evolving, with numerous advancements and promising therapies on the horizon. The increasing incidence of this aggressive cancer underscores the urgent need for innovative treatments that can address the challenges of disease heterogeneity and drug resistance. The introduction of targeted therapies, like <a href=\"https:\/\/www.delveinsight.com\/report-store\/trastuzumab-biosimilars-insight\"><strong>trastuzumab<\/strong><\/a>, <strong>pertuzumab,<\/strong> and newer ADCs, such as KADCYLA and ENHERTU, has significantly improved patient outcomes. The ongoing development of novel therapeutics and the active engagement of key players in the field highlights a robust pipeline poised to bring forth breakthroughs in metastatic HER2-positive breast cancer management. As research progresses, the future holds promise for more effective and personalized treatment options, aiming to enhance the quality of life and survival rates for patients battling this challenging disease.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/www.delveinsight.com\/report-store\/metastatic-her2-positive-breast-cancer-market\"><img decoding=\"async\" width=\"1024\" height=\"194\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/05\/12133001\/Metastatic-HER2-positive-Breast-Cancer-Market-Outlook--1024x194.png\" alt=\"\" class=\"wp-image-32046\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/05\/12133001\/Metastatic-HER2-positive-Breast-Cancer-Market-Outlook--1024x194.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/05\/12133001\/Metastatic-HER2-positive-Breast-Cancer-Market-Outlook--300x57.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/05\/12133001\/Metastatic-HER2-positive-Breast-Cancer-Market-Outlook--150x28.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/05\/12133001\/Metastatic-HER2-positive-Breast-Cancer-Market-Outlook--768x145.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/05\/12133001\/Metastatic-HER2-positive-Breast-Cancer-Market-Outlook--1536x291.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/05\/12133001\/Metastatic-HER2-positive-Breast-Cancer-Market-Outlook-.png 1584w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n","protected":false},"excerpt":{"rendered":"<p>Breast cancer is not a single disease leading to abnormal cell division in breast tissues. Breast cancer is the most common form of cancer in women. Each year, it affects over 2 million women globally and is the most significant cause of death among women.&nbsp; According to DelveInsight\u2019s estimates, there were around 297K new cases [&hellip;]<\/p>\n","protected":false},"author":20,"featured_media":29155,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[127,137,17768,17769,17770,2116,395,6029,524],"industry":[17225],"therapeutic_areas":[17228],"class_list":["post-5908","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-breast-cancer","tag-cancer","tag-her2-breast-cancer","tag-her2-breast-cancer-market","tag-her2-breast-cancer-positive","tag-immunomedics","tag-merck","tag-metastatic-her2-positive-breast-cancer","tag-roche","industry-pharmaceutical","therapeutic_areas-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Metastatic HER2-Positive Breast Cancer Landscape<\/title>\n<meta name=\"description\" content=\"The Metastatic HER-2 Positive Breast Cancer market comprises a variety of treatment options, which is mainly categorized into...\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/metastatic-her2-positive-breast-cancer\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Metastatic HER2-Positive Breast Cancer Landscape\" \/>\n<meta property=\"og:description\" content=\"The Metastatic HER-2 Positive Breast Cancer market comprises a variety of treatment options, which is mainly categorized into...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/metastatic-her2-positive-breast-cancer\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2024-08-08T05:30:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-28T06:43:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/08\/16094802\/HER2-Positive-Breast-Cancer.png\" \/>\n\t<meta property=\"og:image:width\" content=\"466\" \/>\n\t<meta property=\"og:image:height\" content=\"284\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Jatin Vimal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Jatin Vimal\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Metastatic HER2-Positive Breast Cancer Landscape","description":"The Metastatic HER-2 Positive Breast Cancer market comprises a variety of treatment options, which is mainly categorized into...","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/metastatic-her2-positive-breast-cancer","og_locale":"en_US","og_type":"article","og_title":"Metastatic HER2-Positive Breast Cancer Landscape","og_description":"The Metastatic HER-2 Positive Breast Cancer market comprises a variety of treatment options, which is mainly categorized into...","og_url":"https:\/\/www.delveinsight.com\/blog\/metastatic-her2-positive-breast-cancer","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2024-08-08T05:30:00+00:00","article_modified_time":"2025-05-28T06:43:33+00:00","og_image":[{"width":466,"height":284,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/08\/16094802\/HER2-Positive-Breast-Cancer.png","type":"image\/png"}],"author":"Jatin Vimal","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Jatin Vimal","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/metastatic-her2-positive-breast-cancer","url":"https:\/\/www.delveinsight.com\/blog\/metastatic-her2-positive-breast-cancer","name":"Metastatic HER2-Positive Breast Cancer Landscape","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/metastatic-her2-positive-breast-cancer#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/metastatic-her2-positive-breast-cancer#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/08\/16094802\/HER2-Positive-Breast-Cancer.png","datePublished":"2024-08-08T05:30:00+00:00","dateModified":"2025-05-28T06:43:33+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/c846f0323e948c55336d657b654f3158"},"description":"The Metastatic HER-2 Positive Breast Cancer market comprises a variety of treatment options, which is mainly categorized into...","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/metastatic-her2-positive-breast-cancer"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/metastatic-her2-positive-breast-cancer#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/08\/16094802\/HER2-Positive-Breast-Cancer.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/08\/16094802\/HER2-Positive-Breast-Cancer.png","width":466,"height":284,"caption":"HER2-Positive Breast Cancer"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/c846f0323e948c55336d657b654f3158","name":"Jatin Vimal","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/10dcf4b5071c366691525fa20af33b87e8a3897e6d0acc1a2b09a7b99b8d8ae1?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/10dcf4b5071c366691525fa20af33b87e8a3897e6d0acc1a2b09a7b99b8d8ae1?s=96&d=mm&r=g","caption":"Jatin Vimal"},"sameAs":["https:\/\/www.delveinsight.com"]}]}},"author_meta":{"display_name":"Jatin Vimal","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/jatin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/08\/16094802\/HER2-Positive-Breast-Cancer-300x183.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Breast Cancer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Cancer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">HER2 Breast Cancer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">HER2 Breast Cancer Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">HER2 Breast Cancer Positive<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Immunomedics<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Merck<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Metastatic HER2-Positive Breast Cancer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Roche<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Breast Cancer<\/span>","<span class=\"advgb-post-tax-term\">Cancer<\/span>","<span class=\"advgb-post-tax-term\">HER2 Breast Cancer<\/span>","<span class=\"advgb-post-tax-term\">HER2 Breast Cancer Market<\/span>","<span class=\"advgb-post-tax-term\">HER2 Breast Cancer Positive<\/span>","<span class=\"advgb-post-tax-term\">Immunomedics<\/span>","<span class=\"advgb-post-tax-term\">Merck<\/span>","<span class=\"advgb-post-tax-term\">Metastatic HER2-Positive Breast Cancer<\/span>","<span class=\"advgb-post-tax-term\">Roche<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 2 years ago","modified":"Updated 10 months ago"},"absolute_dates":{"created":"Posted on Aug 8, 2024","modified":"Updated on May 28, 2025"},"absolute_dates_time":{"created":"Posted on Aug 8, 2024 11:00 am","modified":"Updated on May 28, 2025 12:13 pm"},"featured_img_caption":"HER2-Positive Breast Cancer","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/5908","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/20"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=5908"}],"version-history":[{"count":5,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/5908\/revisions"}],"predecessor-version":[{"id":32321,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/5908\/revisions\/32321"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/29155"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=5908"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=5908"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=5908"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=5908"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=5908"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}